RENO, Nev., Sept. 4, 2012 /PRNewswire/ -- Lifeline Biotechnologies, Inc. (OTC Market: LLBO) announces the award of US Patent #8,226,572 B2 for Methods for Collecting and Analyzing Thermal Data Based on Breast Surface Temperature to Determine Suspect Conditions.
"This Methods patent adds to our core intellectual property along with the device patent we received this past May and for our previously FDA approved 510(k) medical device" says Jim Holmes, Chairman/CEO. "Our basis for originally applying for the three software patents was as a result of the software technical work completed by world renowned pattern recognition specialists we engaged at Nanyang Technological University, Singapore. Once they had modified and improved our technology capabilities to achieve acceptable and competitive accuracy, sensitivity (false positive) and specificity (false negative) utilizing our patient data, we were convinced our processes were patentable. This novel and exciting technology holds the potential to change the way early breast tissue abnormalities and breast cancers are detected" concluded Holmes.
First Warning Systems, Lifeline Biotechnologies' exclusive licensee, is currently updating the patient data collection device and its interpretive software to complete the product package in preparation for market entry. First Warning is conducting a funding round. See firstwarningsystems.com/investors.html for more information.
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in Reno, NV. FWS' principal shareholder is Lifeline Biotechnologies, Inc. Lifeline has licensed FWS with the worldwide exclusive right for development, manufacturing, marketing and commercialization of its intellectual property. The product is a device and process that detects breast tissue abnormalities. Many of these tissue abnormalities
|SOURCE Lifeline Biotechnologies, Inc.|
Copyright©2012 PR Newswire.
All rights reserved